Guizhou Sanli PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Guizhou Sanli PharmaceuticalLtd de 21.4% y 21.8% por año respectivamente. Se prevé que el BPA crezca en un 22% al año. Se espera que la rentabilidad financiera sea de 19.9% en 3 años.

Información clave

21.4%

Tasa de crecimiento de los beneficios

22.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.8%
Tasa de crecimiento de los ingresos	21.8%
Rentabilidad financiera futura	19.9%
Cobertura de analistas	Low
Última actualización	29 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

We Ran A Stock Scan For Earnings Growth And Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Passed With Ease

Oct 16

Little Excitement Around Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Earnings

Aug 25

Is Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Trading At A 20% Discount?

Aug 03

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Apr 23

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Mar 25

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 06

Previsiones de crecimiento de beneficios e ingresos

SHSE:603439 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,545	522	N/A	482	3
12/31/2025	2,976	429	N/A	566	3
12/31/2024	2,456	343	N/A	68	3
9/30/2024	2,113	329	137	184	N/A
6/30/2024	1,925	309	149	206	N/A
3/31/2024	1,708	294	205	284	N/A
12/31/2023	1,635	293	168	277	N/A
9/30/2023	1,461	256	215	334	N/A
6/30/2023	1,402	238	200	309	N/A
3/31/2023	1,392	232	81	236	N/A
12/31/2022	1,201	201	173	293	N/A
9/30/2022	1,035	144	42	147	N/A
6/30/2022	992	147	54	148	N/A
3/31/2022	968	153	165	182	N/A
12/31/2021	939	152	129	155	N/A
9/30/2021	881	157	125	174	N/A
6/30/2021	725	117	34	103	N/A
3/31/2021	612	92	36	101	N/A
12/31/2020	630	94	12	63	N/A
9/30/2020	676	88	51	78	N/A
6/30/2020	818	124	121	125	N/A
3/31/2020	888	137	85	92	N/A
12/31/2019	884	133	108	116	N/A
6/30/2019	771	108	91	97	N/A
3/31/2019	754	104	111	112	N/A
12/31/2018	722	110	74	75	N/A
6/30/2018	700	120	N/A	67	N/A
3/31/2018	665	106	N/A	46	N/A
12/31/2017	638	88	N/A	57	N/A
9/30/2017	597	77	N/A	43	N/A
6/30/2017	556	66	N/A	28	N/A
3/31/2017	501	68	N/A	19	N/A
12/31/2016	515	75	N/A	35	N/A
9/30/2016	464	69	N/A	30	N/A
6/30/2016	414	63	N/A	26	N/A
3/31/2016	386	58	N/A	29	N/A
12/31/2015	359	53	N/A	33	N/A
9/30/2015	325	46	N/A	28	N/A
6/30/2015	291	40	N/A	23	N/A
3/31/2015	279	34	N/A	12	N/A
12/31/2014	267	29	N/A	1	N/A
12/31/2013	159	19	N/A	30	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.4% al año) de 603439 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (21.4% al año) de 603439 crezcan menos que el mercado CN (26.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 603439 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (21.8% al año) de 603439 crezcan más rápidamente que los del mercado CN (13.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (21.8% al año) de 603439 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 603439 sea baja dentro de 3 años (19.9%).

Guizhou Sanli PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.14 in 3Q 2023)

We Ran A Stock Scan For Earnings Growth And Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Passed With Ease

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) announces an Equity Buyback for 6,722,700 shares, representing 1.64% for CNY 120 million.

Hainan Yuexin Pharmaceutical Investment Partnership (General Partnership) acquired 5.12% stake in Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) from Zhang Hai for approximately CNY 220 million.

Second quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2023)

Little Excitement Around Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Earnings

Now 22% undervalued after recent price drop

Is Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) Trading At A 20% Discount?

Now 20% undervalued after recent price drop

Guizhou Sanli Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 29, 2024

Guizhou Sanli Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 1Q 2023)

Now 20% overvalued

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Intrinsic Value Is Potentially 73% Above Its Share Price

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024

Guizhou Sanli PharmaceuticalLtd (SHSE:603439) Seems To Use Debt Rather Sparingly

Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Now 22% undervalued

Now 21% undervalued

Now 20% undervalued

Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) announces an Equity Buyback for CNY 40 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.089 in 3Q 2022)

Guizhou Sanli Pharma Plans Acquisition for CNY 499.6 Million

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.10 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 19%

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.089 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 2Q 2021)

GuiZhou SanLi Pharmaceutical Co.,Ltd (SHSE:603439) signed framework agreement to acquire 51% stake in Guizhou Haosite Biotechnology Co., Ltd. from Zhao Guofu.

First quarter 2022 earnings released: EPS: CN¥0.06 (vs CN¥0.06 in 1Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

GuiZhou SanLi Pharmaceutical Co., Ltd. (SHSE:603439) agreed to acquire 95% stake in Guiyang Dechang Xiang Pharmaceutical Co., Ltd from Guizhou Jingyi Garden Ecological Planting Co., Ltd. and Guiyang Dechang Xiang Pharmaceutical Co., Ltd.’s Trade Union Committee for CNY 230 million.

Now 21% undervalued

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.005 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.053 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.24 (vs CN¥0.36 in FY 2019)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥15.39

New 90-day low: CN¥18.03

New 90-day low: CN¥20.70

Third quarter earnings released

New 90-day low: CN¥23.10

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low - CN¥26.68

First half earnings released

First half earnings released

GuiZhou SanLi Pharmaceutical Co.,LTD. to Report First Half, 2020 Results on Aug 28, 2020

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento